We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
Cap. Flow
+$12.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$36.1M
3
SNY icon
Sanofi
SNY
+$34.1M
4
CYTK icon
Cytokinetics
CYTK
+$31.4M
5
WAT icon
Waters Corp
WAT
+$25.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$147M
2
PTCT icon
PTC Therapeutics
PTCT
+$72.4M
3
IMVT icon
Immunovant
IMVT
+$55.7M
4
DDOG icon
Datadog
DDOG
+$31.8M
5
AVNS
Avanos Medical
AVNS
+$28M

Sector Composition

Rank Sector Weight
1 Miscellaneous 55.89%
2 Healthcare 30.09%
3 Technology 6.58%
4 Consumer Discretionary 3.42%
5 Communication Services 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$2.39B 29.24%
3,200,000
+1,100,000
+52% +$798M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$81.1B
$1.74B 21.32%
5,800,000
+2,300,000
+66% +$646M
MDGL icon
3
Madrigal Pharmaceuticals
MDGL
$12.4B
$155M 1.89%
288,000
+23,417
+9% +$12M
CYTK icon
4
CALL
Cytokinetics
CYTK
$10.2B
$130M 1.59%
1,530,000
-170,000
-10% -$12.2M
SUPN icon
5
Supernus Pharmaceuticals
SUPN
$2.55B
$123M 1.51%
2,646,201
+750,854
+40% +$36.1M
AGIO icon
6
CALL
Agios Pharmaceuticals
AGIO
$1.98B
$104M 1.28%
2,810,000
-390,000
-12% -$11.8M
CYTK icon
7
Cytokinetics
CYTK
$10.2B
$102M 1.25%
1,201,342
+436,804
+57% +$31.4M
INCY icon
8
Incyte
INCY
$25.7B
$102M 1.25%
900,005
+243,188
+37% +$24.1M
NBIX icon
9
Neurocrine Biosciences
NBIX
$16B
$90.3M 1.1%
535,838
-188,162
-26% -$27.9M
TVTX icon
10
Travere Therapeutics
TVTX
$6.19B
$89.3M 1.09%
1,572,539
-3,324,878
-68% -$147M
AGIO icon
11
Agios Pharmaceuticals
AGIO
$1.98B
$89.1M 1.09%
2,400,000
-316,000
-12% -$9.59M
PTCT icon
12
PTC Therapeutics
PTCT
$5.85B
$87.4M 1.07%
1,071,395
-1,003,054
-48% -$72.4M
UNH icon
13
UnitedHealth
UNH
$356B
$76.1M 0.93%
183,000
+35,000
+24% +$13M
FRPT icon
14
Freshpet
FRPT
$3.37B
$74.5M 0.91%
1,260,702
+167,395
+15% +$9.58M
DYN icon
15
Dyne Therapeutics
DYN
$4.55B
$68.6M 0.84%
3,087,226
-87,884
-3% -$1.63M
AMZN icon
16
Amazon
AMZN
$2.77T
$67.8M 0.83%
284,562
+22,425
+9% +$5.63M
IMVT icon
17
Immunovant
IMVT
$8.05B
$66.9M 0.82%
1,736,000
-1,828,916
-51% -$55.7M
RIGL icon
18
Rigel Pharmaceuticals
RIGL
$904M
$65.4M 0.8%
1,672,000
+392,000
+31% +$12.1M
TMO icon
19
Thermo Fisher Scientific
TMO
$226B
$61.4M 0.75%
122,480
+30,989
+34% +$14.9M
IRWD icon
20
Ironwood Pharmaceuticals
IRWD
$706M
$58.7M 0.72%
13,932,000
-1,096,000
-7% -$4.22M
HRMY icon
21
Harmony Biosciences
HRMY
$2.43B
$56.9M 0.7%
1,564,000
-60,000
-4% -$1.89M
REGN icon
22
Regeneron Pharmaceuticals
REGN
$86.1B
$56M 0.69%
89,809
+53,683
+149% +$36.5M
PTCT icon
23
CALL
PTC Therapeutics
PTCT
$5.85B
$53.8M 0.66%
660,000
+270,000
+69% +$19.5M
NKTR icon
24
Nektar Therapeutics
NKTR
$2.53B
$50.5M 0.62%
724,000
+146,000
+25% +$10.7M
MLYS icon
25
Mineralys Therapeutics
MLYS
$2.46B
$46.8M 0.57%
1,736,000
+560,000
+48% +$15.4M
1
2 3 4 5

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.

  • Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
  • Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
  • Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
  • Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
  • Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
  • Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.